The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2018

Filed:

Oct. 15, 2015
Applicant:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Inventors:

Andrew Koff, Westbury, NY (US);

Aimee Crago, New York, NY (US);

David Liu, Elmhurst, NY (US);

Marta Kovatcheva, New York, NY (US);

Samuel Singer, New York, NY (US);

Gary K. Schwartz, New York, NY (US);

Mark A. Dickson, New York, NY (US);

Mary Elizabeth Klein, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/519 (2006.01); C12Q 1/68 (2006.01); G01N 33/574 (2006.01); G01N 33/573 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); C12Q 1/6886 (2013.01); G01N 33/573 (2013.01); G01N 33/57484 (2013.01); G01N 33/57496 (2013.01); C12Q 2563/131 (2013.01); G01N 2333/9015 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.


Find Patent Forward Citations

Loading…